Genelex.com - Genelex | LinkedIn

Provided by Alexa ranking, genelex.com has ranked N/A in N/A and 7,277,932 on the world. genelex.com reaches roughly 424 users per day and delivers about 12,707 users each month. The domain genelex.com uses a Commercial suffix and it's server(s) are located in N/A with the IP number 18.238.192.110 and it is a .com domain.

WebFounded in 1987, Genelex is a highly accredited leader in precision medication management and one of the first clinical laboratories to provide pharmacogenetic testing and interpretation as...

List of domain same IP 18.238.192.110

Keywords on this domain

genelex

genelex tamoxifen

genelex dna testing

genelex nivelles

genelex 6v6

genalex tubes

genelex testing

genelex corporation

genalex kt88

genelec speakers

genelex lab

genelex jobs

Search Results related to genelex.com on Search Engine

  • Genelex | LinkedIn

    linkedin.com

    https://www.linkedin.com/company/genelex

    WebFounded in 1987, Genelex is a highly accredited leader in precision medication management and one of the first clinical laboratories to provide pharmacogenetic testing and interpretation as...

    DA: 57 PA: 57 MOZ Rank: 95

  • Invitae to Acquire YouScript and Genelex to Make it Easier to Use

    invitae.com

    https://ir.invitae.com/news-and-events/press-releases/press-release-details/2020/Invitae-to-Acquire-YouScript-and-Genelex-to-Make-it-Easier-to-Use-Pharmacogenetic-Information-at-the-Point-of-Care/default.aspx

    WebSAN FRANCISCO, March 10, 2020 /PRNewswire/ -- Invitae Corporation (NYSE: NVTA), a leading medical genetics company, today announced it has entered into definitive agreements to acquire YouScript, a privately held clinical decision support and analytics platform, and Genelex, a privately held pharmacogenetic testing company, to bring best-in ...

    DA: 98 PA: 31 MOZ Rank: 47

  • Invitae to Acquire YouScript and Genelex to Make it Easier to Use

    prnewswire.com

    https://www.prnewswire.com/news-releases/invitae-to-acquire-youscript-and-genelex-to-make-it-easier-to-use-pharmacogenetic-information-at-the-point-of-care-301021041.html

    WebSAN FRANCISCO, March 10, 2020 /PRNewswire/ -- Invitae Corporation (NYSE: NVTA ), a leading medical genetics company, today announced it has entered into definitive agreements to acquire YouScript,...

    DA: 73 PA: 60 MOZ Rank: 91

  • Working at Genelex Corp | Glassdoor

    glassdoor.com

    https://www.glassdoor.com/Overview/Working-at-Genelex-Corp-EI_IE274801.11,23.htm

    WebGenelex is a leader in personalized medication management. A pioneer in DNA testing since 1987, Genelex now focuses exclusively on pharmacogenetic testing and clinical decision support software that evaluates potential drug-drug and gene-drug interactions.

    DA: 80 PA: 88 MOZ Rank: 47

  • Agena Bioscience Names Genelex as Certified Service Provider for

    genelex.com

    https://www.genelex.com/2016/08/29/agena-bioscience-names-genelex-as-certified-service-provider-for-targeted-genetic-analysis/

    WebAug 29, 2016 · As a Certified Service Provider, Genelex will provide dedicated customer support, customizable assay design, test development and validation across multiple platforms. The laboratory has integrated robotics and secure Laboratory Information Systems to ensure high accuracy, low error, and rapid turnaround on results.

    DA: 25 PA: 68 MOZ Rank: 43

  • Tests | Genelex

    genelex.jp

    http://genelex.jp/pharmacogenetic-tests/

    WebGenelex has been a leader in pharmacogenetic testing since 2000. Our high-complexity laboratory facilities feature: Robotic DNA extraction and testing, to ensure high accuracy and low error; Proprietary test platforms and methodologies; Testing for more allele mutations than any other system; Test validation across multiple platforms

    DA: 81 PA: 2 MOZ Rank: 87

  • Medical genetics company Invitae acquires YouScript, Genelex, Diploid …

    spglobal.com

    https://www.spglobal.com/marketintelligence/en/news-insights/latest-news-headlines/medical-genetics-company-invitae-acquires-youscript-genelex-diploid-for-195m-57515588

    WebMar 11, 2020 · Invitae will acquire pharmacogenetic testing company Genelex for about $20.7 million in Invitae common shares plus additional shares, if certain milestones are met. The two acquisitions are likely to close in the coming weeks, pending customary closing conditions.

    DA: 35 PA: 43 MOZ Rank: 48

  • Genelex announces new genetic testing options - youscript.com

    youscript.com

    https://youscript.com/genelex-announces-new-genetic-testing-options/

    WebGenelex is unveiling five new panels and 17 new genetic testing options to augment our existing panel of six tests that form the core of the YouScript Personalized Prescribing System. In conjunction with the YouScript Personalized Prescribing software, all are designed to improve providers’ ability to further personalize medication therapy ...

    DA: 65 PA: 79 MOZ Rank: 83

  • Genelex Corp. - Home - Facebook

    facebook.com

    https://www.facebook.com/GenelexCorp/

    WebAbout. See all. Pioneering genetic testing since 1987. Creator of the revolutionary software YouScript. Committed to enhancing the health and safety of society. Originally founded as a …

    DA: 32 PA: 7 MOZ Rank: 23

  • Genelex - Crunchbase Company Profile & Funding

    crunchbase.com

    https://www.crunchbase.com/organization/genelex

    WebGenelex is a leader in precision medication management. A pioneer in DNA testing since 1987, Genelex now focuses exclusively on pharmacogenetic testing. Backed by a powerful combination of innovative analytics software, state-of art laboratory facilities, and expert staff, Genelex has a longstanding commitment to the prevention of dangerous and.

    DA: 13 PA: 83 MOZ Rank: 1

Alexa Rank

Alexa

GLOBAL RANK

7,277,932
Alexa

Alexa Reach

0.0000186982
Alexa

Page length

N/A
Alexa

Alexa Rank Country N/A

N/A
Alexa

Daily Unique Visitors

424
Alexa

Monthly Unique Visitors

12,707

Vistor via Country

Country lang
Country code
Total visitor

United States

US

2,718

Indonesia

ID

2,126

Taiwan

TW

691

United Kingdom

GB

614

Brazil

BR

555

Nigeria

NG

485

Egypt

EG

408

Hong Kong

HK

385

Canada

CA

385

Australia

AU

335

Philippines

PH

240

India

IN

234

Malaysia

MY

230

Spain

ES

191

Germany

DE

186

Mexico

MX

178

France

FR

168

Italy

IT

155

Turkey

TR

142

Iraq

IQ

130

Thailand

TH

127

Netherlands

NL

122

Israel

IL

121

Cambodia

km

100

Algeria

DZ

78

Ireland

IE

70

Romania

RO

67

Jordan

JO

62

Poland

PL

60

Ghana

GH

57

Argentina

AR

55

South Africa

ZA

50

Belgium

BE

44

Czechia

CZ

41

Ukraine

UA

38

Japan

JA

38

Morocco

MA

37

South Korea

KO

36

Lebanon

LB

34

Saudi Arabia

SA

33

Austria

AT

32

Hungary

HU

30

Sweden

SE

29

Singapore

SG

28

Pakistan

PK

27

Bangladesh

BD

25

Denmark

DK

24

Greece

GR

23

Alexa Traffic Graph

Alexa daily traffic trend graph
Alexa Statistics Graph for genelex.com
Alexa daily pageviews (percent) graph
Alexa Statistics Graph for www.nahklick.de
Alexa daily pageviews per user graph
Alexa Statistics Graph for genelex.com
Alexa time on site (in minutes) graph
Alexa Statistics Graph for www.nahklick.de
Alexa bounce rate (percent) graph
Alexa Statistics Graph for genelex.com
Alexa search visits graph
Alexa Statistics Graph for genelex.com

SEOquake Zone

Title Tips
Description Tips
Keywords Tips
Viewport Tips
Icon
UTF-8

Mini site formation by Alexa Rank

MOZ Rank

DA
13

PA
83

MOZ Rank
1

DNS Record

Host Type Class TTL Extra
genelex.com A IN 60 Ip: 18.164.154.86
genelex.com A IN 60 Ip: 18.164.154.10
genelex.com A IN 60 Ip: 18.164.154.38
genelex.com A IN 60 Ip: 18.164.154.36
genelex.com NS IN 21600 Target: ns-1501.awsdns-59.org
genelex.com NS IN 21600 Target: ns-1748.awsdns-26.co.uk
genelex.com NS IN 21600 Target: ns-318.awsdns-39.com
genelex.com NS IN 21600 Target: ns-992.awsdns-60.net
genelex.com SOA IN 900 Mname: ns-318.awsdns-39.com
Rname: awsdns-hostmaster.amazon.com
Serial: 1
Refresh: 7200
Retry: 900
Expire: 1209600
Minimum-ttl: 86400
genelex.com MX IN 300 Pri: 10
Target: mailstream-central.mxrecord.mx
genelex.com MX IN 300 Pri: 5
Target: mailstream-east.mxrecord.io
genelex.com MX IN 300 Pri: 5
Target: mailstream-west.mxrecord.io
genelex.com TXT IN 600 Txt: MS=ms47792311
Entries_0: MS=ms47792311
genelex.com TXT IN 600 Txt: dg7rl293mkupvhcoketmb9fnaj
Entries_0: dg7rl293mkupvhcoketmb9fnaj
genelex.com TXT IN 600 Txt: facebook-domain-verification=69ip9mn8su6svv4evi45lp5aaxxlit
Entries_0: facebook-domain-verification=69ip9mn8su6svv4evi45lp5aaxxlit
genelex.com TXT IN 600 Txt: genelex.azurewebsites.net
Entries_0: genelex.azurewebsites.net
genelex.com TXT IN 600 Txt: genelex.com. IN TXTv=spf1aip4:63.146.212.130?all
Entries_0: genelex.com. IN TXT
Entries_1: v=spf1
Entries_2: a
Entries_3: ip4:63.146.212.130
Entries_4: ?all
genelex.com TXT IN 600 Txt: google-site-verification=6NPUTEbpGmzjODPRksv32BoFfFf43Rdy83IvnQ7wVX0
Entries_0: google-site-verification=6NPUTEbpGmzjODPRksv32BoFfFf43Rdy83IvnQ7wVX0
genelex.com TXT IN 600 Txt: google-site-verification=C32uWSFHlrp0mx6DKbyGEzZbQ5q1-n1_WjdLzY7I0oI
Entries_0: google-site-verification=C32uWSFHlrp0mx6DKbyGEzZbQ5q1-n1_WjdLzY7I0oI
genelex.com TXT IN 600 Txt: google-site-verification=jcEnkwQLvIC_r6R1Wh4kquQfVFYAnQGRaeozRHFah4w
Entries_0: google-site-verification=jcEnkwQLvIC_r6R1Wh4kquQfVFYAnQGRaeozRHFah4w
genelex.com TXT IN 600 Txt: v=spf1 mx ip4:63.146.212.130 include:mktomail.com include:e2ma.net include:sendgrid.net ~all
Entries_0: v=spf1 mx ip4:63.146.212.130 include:mktomail.com include:e2ma.net include:sendgrid.net ~all

Hosting and Whois Zone

IP 18.238.192.68
Domain infomation Domain Name: GENELEX.COM
Registry Domain ID: 942_DOMAIN_COM-VRSN
Registrar WHOIS Server: whois.godaddy.com
Registrar URL: http://www.godaddy.com
Updated Date: 2023-06-12T22:54:58Z
Creation Date: 1995-06-14T04:00:00Z
Registry Expiry Date: 2025-06-13T04:00:00Z
Registrar: GoDaddy.com, LLC
Registrar IANA ID: 146
Registrar Abuse Contact Email: [email protected]
Registrar Abuse Contact Phone: 480-624-2505
Domain Status: clientDeleteProhibited https://icann.org/epp#clientDeleteProhibited
Domain Status: clientRenewProhibited https://icann.org/epp#clientRenewProhibited
Domain Status: clientTransferProhibited https://icann.org/epp#clientTransferProhibited
Domain Status: clientUpdateProhibited https://icann.org/epp#clientUpdateProhibited
Name Server: NS-1501.AWSDNS-59.ORG
Name Server: NS-1748.AWSDNS-26.CO.UK
Name Server: NS-318.AWSDNS-39.COM
Name Server: NS-992.AWSDNS-60.NET
DNSSEC: unsigned
URL of the ICANN Whois Inaccuracy Complaint Form: https://www.icann.org/wicf/
>>> Last update of whois database: 2024-04-19T17:38:02Z <<<

For more information on Whois status codes, please visit https://icann.org/epp

NOTICE: The expiration date displayed in this record is the date the
registrar's sponsorship of the domain name registration in the registry is
currently set to expire. This date does not necessarily reflect the expiration
date of the domain name registrant's agreement with the sponsoring
registrar. Users may consult the sponsoring registrar's Whois database to
view the registrar's reported date of expiration for this registration.

TERMS OF USE: You are not authorized to access or query our Whois
database through the use of electronic processes that are high-volume and
automated except as reasonably necessary to register domain names or
modify existing registrations; the Data in VeriSign Global Registry
Services' ("VeriSign") Whois database is provided by VeriSign for
information purposes only, and to assist persons in obtaining information
about or related to a domain name registration record. VeriSign does not
guarantee its accuracy. By submitting a Whois query, you agree to abide
by the following terms of use: You agree that you may use this Data only
for lawful purposes and that under no circumstances will you use this Data
to: (1) allow, enable, or otherwise support the transmission of mass
unsolicited, commercial advertising or solicitations via e-mail, telephone,
or facsimile; or (2) enable high volume, automated, electronic processes
that apply to VeriSign (or its computer systems). The compilation,
repackaging, dissemination or other use of this Data is expressly
prohibited without the prior written consent of VeriSign. You agree not to
use electronic processes that are automated and high-volume to access or
query the Whois database except as reasonably necessary to register
domain names or modify existing registrations. VeriSign reserves the right
to restrict your access to the Whois database in its sole discretion to ensure
operational stability. VeriSign may restrict or terminate your access to the
Whois database for failure to abide by these terms of use. VeriSign
reserves the right to modify these terms at any time.

The Registry database contains ONLY .COM, .NET, .EDU domains and
Registrars.